Alterity Therapeutics Ltd ATHE:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/05/21 EST
1.37quote price arrow down-0.05 (-3.52%)
Volume
405,401
52 week range
0.28 - 5.15

...

Loading . . .

KEY STATS

  • Open1.50
  • Day High1.50
  • Day Low1.27
  • Prev Close1.42
  • 52 Week High5.15
  • 52 Week High Date08/04/20
  • 52 Week Low0.28
  • 52 Week Low Date03/20/20
  • Market Cap47.58M
  • Shares Out34.73M
  • 10 Day Average Volume0.37M
  • Dividend-
  • Dividend Yield-
  • Beta1.67
  • 1 Year % Change127.2

RATIOS/PROFITABILITY

  • EPS (TTM)-0.69
  • P/E (TTM)-1.98
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-12.209M
  • ROE (MRQ)-71.91%
  • Revenue (MRQ)10,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-171,861.50%
  • Debt To Equity (MRQ)0.03%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Alterity Therapeutics Ltd News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being...
Geoffrey Kempler
Non-Executive Chairman
David Stamler M.D.
Chief Executive Officer
Kathryn Andrews
Chief Financial Officer
Address
L 3 460 Bourke St
Melbourne, VIC
3000
Australia